Elon Musk’s neurotechnology company, Neuralink, has been granted approval for its first human trial of a brain chip. The clinical trial aims to test the brain implant’s safety and efficacy in helping paralysis patients control a computer cursor or keyboard using their thoughts. Patients in the trial may include those with paralysis due to neck injuries or amyotrophic lateral sclerosis.

Here are the key details:

Study Duration: The trial is expected to span approximately six years.

Number of Patients: The exact number of patients participating in the trial has not been disclosed. Initially, Neuralink had aimed for 10 patients, but negotiations with the U.S. Food and Drug Administration (FDA) resulted in a revised number due to safety concerns.

Neuralink, founded by Elon Musk in 2016, focuses on developing implantable brain-computer interfaces (BCIs) that can translate thoughts into actions. This technology has the potential to control external devices, restore lost brain functions, and treat various medical conditions, as envisioned by Musk.

While the company has made strides in demonstrating the capabilities of BCIs, it still faces a lengthy journey toward commercial approval, which could take more than a decade, according to experts.

Neuralink’s work represents a significant step in the field of neurotechnology, with potential applications ranging from enhancing human capabilities to addressing medical conditions.

—

#Neuralink #BrainChip #ClinicalTrial #BCI #ElonMusk #Neurotechnology #ParalysisPatients #MedicalInnovation #NeuralImplant #FDAApproval